🇺🇸 FDA
Pipeline program

Matching orodispersible placebo tablet

P22-04 / BP1.7881

Phase 2 small_molecule active

Quick answer

Matching orodispersible placebo tablet for Eosinophilic esophagitis is a Phase 2 program (small_molecule) at Bioprojet Pharma with 1 ClinicalTrials.gov record(s).

Program details

Company
Bioprojet Pharma
Indication
Eosinophilic esophagitis
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials